Nasdaq:US$15.78 (+0.12) | HKEX:HK$24.75 (+0.75) | AIM:£2.47 (+0.03)
News & Presentations
Previous Article   |   Next Article
Group, Press Releases | 11 Nov 2019

Chi-Med to Attend Upcoming Investor and Industry Conferences

London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the following conferences:

  • Deutsche Bank Depositary Receipts Virtual Investor Conference (dbVIC) webcast on Wednesday, November 13, 2019 at 8:30 am (EST) / 1:30 pm (GMT) / 9:30 pm (China Time);
  • BioCentury & Bayhelix China Healthcare Summit on Wednesday, November 20, 2019 at 1:30 pm (China Time) in Shanghai; and
  • Presentation at Piper Jaffray Annual Healthcare Conference on Tuesday, December 3, 2019 at 8:50 am (EST), and investor meetings on Tuesday, December 3, 2019 in New York.


In addition, members of the management team will attend the following investor conferences:

  • Presentation at Jefferies University Specialist Speakers Summit on China Disruption & Innovation on Friday, November 15, 2019 in Hong Kong;
  • Investor meetings at Jefferies London Healthcare Conference on Wednesday, November 20, 2019 and Thursday, November 21, 2019 in London;
  • Investor meetings at Morgan Stanley Annual Asia Pacific Summit on Thursday, November 21, 2019 in Singapore; and
  • Presentation at Goldman Sachs Asia Pacific Healthcare Forum on Monday, November 25, 2019 at 11:30 am (Hong Kong Time), and investor meetings on Monday, November 25, 2019 and Tuesday, November 26, 2019 in Hong Kong.


Further information are available at in the Shareholder Information section under “Events, Circulars & Forms.”


About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 470 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit:


Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.



Investor Enquiries

Mark Lee, Senior Vice President, Corporate Finance & Development
+852 2121 8200

Annie Cheng, Vice President, Corporate Finance & Development
+1 (973) 567 3786

David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)

Xuan Yang, Solebury Trout
+1 (415) 971 9412 (Mobile)

Media Enquiries

UK & Europe – Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)

Americas – Brad Miles, Solebury Trout
+1 (917) 570 7340 (Mobile)

Hong Kong & Asia ex-China – Joseph Chi Lo, Brunswick
+852 9850 5033 (Mobile)

Hong Kong & Asia ex-China – Zhou Yi, Brunswick
+852 9783 6894 (Mobile)

Mainland China – Sam Shen, Edelman
+86 1367 179 1029 (Mobile)

Nominated Advisor

Atholl Tweedie, Panmure Gordon (UK) Limited
+44 (20) 7886 2500